| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
Double-stranded RNA (dsRNA) is well characterized as an inducer of antiviral interferon responses. We found that the systemic immune-activating capacity of the plant-derived dsRNA protected mice from infection by H1N1 strain of the Influenza A virus. Further, this dsRNA exhibited protective effect against a highly virulent H5N1 strain of the Influenza A virus. In addition, subcutaneous inoculation of the dsRNA together with inactivated virion of the H5N1 strain of the Influenza A virus suppressed the lethality by the viral infection as compared with individual inoculation of either dsRNA or HA protein, suggesting its potential usage as a vaccination adjuvant. Moreover, intraperitoneal inoculation of the dsRNA limited the growth of B16-F10 melanoma cells through the activation of NK cells in murine models. Taken together, this study demonstrated the systemic immune-modulating capacity of a plant-derived dsRNA and its potential for nucleic acid-based clinical applications.
|
